How to reach us: Austria, Czech Republic, France, Germany, Italy, Poland, Spain, Switzerland, Turkey and Great Britain "Our goal: to develop an effective cancer therapy for the successful treatment of patients worldwide.” Dr. Ben J. Lipps CEO 1997 Foundation of our headquarters in Berlin 17 Quadrillions iron oxide nanoparticles in just one milliliter of magnetic liquid 17 International patent families approx. 100 individual patents and 65 patent applications 2011 Breakthrough regulatory approval in the EU and first successful patient treatments NanoTherm® fights the tumor from the inside. MagForce is forging new paths in order to treat cancer successfully and gently: With NanoTherm® therapy, we have developed an innovative approach based on nanotechnology, which we want to make available to patients all over the world. And we are getting closer and closer to this goal: NanoTherm® is the first and only nanotechnology-based therapy with European approval for the treatment of brain tumors. To date, over 100 patients have already been treated using our NanoTherm® therapy. In Germany alone, five renowned clinics are already equipped with our patented equipment and are able to perform NanoTherm® therapies with increasing success. A treatment centre in Lublin, Poland is expected to open soon, while additional treatment centres in Italy and other European countries are planned. A pivotal clinical study for the treatment of prostate cancer has been ongoing in the USA since July 2018 at selected specialised medical centres. Here, the goal is to obtain evidence for the effectiveness of the therapy, and to subsequently gain regulatory approval of this innovative and gentle therapy in the USA for the time being. 2018 April In Washington and Texas, the ethics commissions (“Institutional Review Board”, IRB) gave two treatment centres in the USA - the University of Washington in Seattle and the Christus Santa Rosa Hospital in San Antonio - the green light to conduct the decisive clinical studies regarding the treatment’s effectiveness in prostate cancer. February 2018 MagForce AG received approval from the American “Food and Drug Administration (FDA)” to conduct a clinical study using the NanoTherm® therapy for focal tumor ablation in prostate cancer with intermediate risk. 2017 November MagForce AG participates in the annual conference of the “Society for NeuroOncology” in San Francisco, USA. The management board Dr. Ben J. Lipps (Chairman) CEO Chairman of the Board of MagForce AG since 2013; previously Chairman of the Board at Fresenius Medical Care/USA; earned his doctorate degree at MIT in Boston. FIND OUT MORE Christian von Volkmann CFO Member of the Board at MagForce AG since 2012. Experienced specialist in corporate finance, capital market and corporate transactions and corporate structuring. FIND OUT MORE The supervisory board Stefan Schütze Supervisory board Stefan Schütze is attorney at law and currently managing partner of C3 Management GmbH, an asset management company focused on managing venture capital fonds. FIND OUT MORE Klemens Hallman Supervisory board Involved as a member of the supervisory board and core shareholder of MagForce AG. Founder of the Austrian real estate company HALLMANN. FIND OUT MORE Aaron Weaver Supervisory board Aaron Weaver is a Managing Director at Apeiron Investments focused on investing and coordinating capital markets activities into the life sciences sector. FIND OUT MORE Our therapy Find out more about the NanoTherm® therapy. Careers at MagForce Shape the future of cancer therapy with us. Yes, I agree to the processing and use of my personal data in accordance with the Privacy Policy for the purpose of contacting. This website uses Google Analytics to improve future content. Please click here to set an opt‑out‑Cookie if you do not want Google Analytics to track your browsing habits. OK Important Pages Our Therapy For Patients Financial Reports Contact News & Events 05.11.21 MagForce AG: MagForce USA, Inc. has Received FDA’s Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System © 2021 MagForce AG, The Nanomedicine Company Privacy Policy Imprint